Introduction {#hyy189s6}
============

Colorectal cancer (CRC) is the third most common cancer worldwide and the most frequently occurring cancer in Japan, with 147 200 new cases and 51 600 deaths reported in 2016 ([@hyy189C1],[@hyy189C2]). In a clinical study, \~25% of the patients had distant metastatic disease at the time of diagnosis, and \~50% of the patients developed metastases during the course of the disease, with liver being the most common site ([@hyy189C3],[@hyy189C4]).

First-line treatment of metastatic CRC (mCRC) is determined based on clinical presentation at diagnosis, patient and tumor characteristics, status of metastases, tumor-related symptoms and patient's preferences. The European Society for Medical Oncology (ESMO) Guidelines of 2012 stratified patients into four subgroups with different treatment intensities, which were defined as follows: Group 0 with resectable metastasis; Group 1 with potentially resectable metastasis after achieving tumor response; Group 2 with non-resectable metastasis, high tumor burden or tumor-related symptoms and Group 3 with unresectable metastasis, initially asymptomatic and less aggressive disease ([@hyy189C5]). Patients belonging to Groups 1 to 3 receive upfront systemic chemotherapy. Patients of Groups 1 and 2 require intensive upfront chemotherapy to ensure secondary resectability or rapid symptom control, whereas Group 3 patients are treated with a sequential treatment approach ([@hyy189C6]).

Cetuximab is a human/mouse chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR) to inhibit its signaling and shows antitumor effects by binding to EGFR, competing with its ligands ([@hyy189C7]). Cetuximab, administered alone or in combination with cytotoxic chemotherapy, showed efficacy in the treatment of patients with *RAS* wild-type CRC ([@hyy189C8],[@hyy189C9]). Cetuximab may yield higher responses with the shrinkage of lesions, potentially leading to long overall survival (OS) in patients with mCRC ([@hyy189C10]--[@hyy189C12]).

There have been no reports of treatment results aiming at estimating the hepatic resection rates, overall survival and incidence of tumor-related symptoms in each group by following the ESMO Guidelines 2012. In addition, in Japan, only a few reports have focused on cetuximab combination therapy as the first-line treatment for mCRC ([@hyy189C13],[@hyy189C14]). This prompted us to conduct the present observational study ([@hyy189C15],[@hyy189C16]). The aims of this study were to clarify the clinical practice and outcomes of first-line cetuximab-containing chemotherapy in patients with *KRAS* wild-type mCRC under practical use in Japan, to collect historical/reference data and to estimate the efficacy of each group classified by the ESMO Guidelines 2012 ([@hyy189C5]).

Patients and methods {#hyy189s7}
====================

Study population {#hyy189s8}
----------------

Cetuximab observational study as first-line therapy (CORAL) is a Japan-based prospective observational study that was conducted at 158 study sites (Table [1](#hyy189TB1){ref-type="table"}). Patients could participate in the study if they met the following criteria: had previously untreated mCRC; had an Eastern Cooperative Oncology Group (ECOG) scale of performance status (PS) of 0--2; were scheduled to receive a first-line chemotherapy regimen containing cetuximab; and provided written informed consent. Patients with multiple primary cancers or previous neoadjuvant chemotherapy for liver metastasis were also included in the study. Patients were considered for this study until death, withdrawal of consent or loss to follow-up. There were no protocol-specified treatments or assessments. All aspects of treatments, including specific chemotherapy agents used alone and/or in combination, dose and schedule, were determined by a physician. The protocol was reviewed by the institutional review board of each participating site. Table 1.Baseline characteristicsGroup 1Group 2Group 3Total*N*165 (100%)224 (100%)173 (100%)562 (100%)Gender Male115 (70%)138 (62%)108 (62%)361 (64%) Female50 (30%)86 (38%)65 (38%)201 (30%)Age Median (range)65 (32--84)65 (31--88)67 (37--87)65 (31--88)ECOG PS 0130 (79%)124 (55%)139 (80%)393 (70%) 132 (19%)82 (37%)29 (17%)143 (25%) 23 (2%)18 (8%)5 (3%)26 (5%)*KRAS* mutation status Wild type156 (95%)216 (96%)166 (96%)538 (96%) Mutation type5 (3%)3 (1%)6 (3%)14 (2%) Not measured2 (1%)2 (1%)1 (1%)5 (1%) Unknown2 (1%)3 (1%)5 (1%)CEA Median (range)13 (0.5--8.3 × 10^3^)63 (0.7--9.8 × 10^4^)27 (0.4--1.0 × 10^5^)29 (0.4--1.0 × 10^5^)LDH \< ULN99 (60%)84 (37%)107 (62%)290 (52%) ≥ULN66 (40%)140 (63%)66 (38%)272 (48%)Primary tumor site Colon99 (60%)154 (69%)117 (67%)370 (66%) Rectum64 (39%)67 (30%)55 (32%)186 (33%) Other2 (1%)3 (1%)1 (1%)6 (1%)Resection of primary tumor Yes117 (71%)102 (46%)149 (86%)368 (65%) No48 (29%)122 (54%)24 (14%)194 (35%)[^1]

Classification according to ESMO Guidelines 2012 {#hyy189s9}
------------------------------------------------

Patients were classified into three groups at enrollment in the present study. Investigator grouped patients into Group 1, 2 or 3 according to 'Hierarchy of factors for definition of treatment aim/group' in ESMO Guidelines 2012. Group 1 was defined as patients with liver or lung metastases which were not completely resectable (*R*~0~ or *R*~1~), Group 2 as patients who were necessary to receive intermediate intensive treatment, where the treatment aim is palliative rather than curative, most reliable and rapid regression of metastases is important, in particular in case of imminent or present symptoms or tumor associated complications and Group 3 as patients who were not necessary to intensive treatment with maximal shrinkage of metastases.

Clinical outcomes {#hyy189s10}
-----------------

The measures of the clinical outcomes were based on a physician's determination and included progression-free survival (PFS) from the date of initiation of first-line treatment to first progressive disease, conversion surgery (with resection margins other than *R*~0~) or death. In case of a conversion surgery performed with *R*~0~ resection, it is considered a censored case at the time of surgery. Other measures included time to treatment failure (TTF) from the date of initiation of first-line treatment to premature treatment discontinuation, to initiation of other treatments, to disease progression or to death for any reason; OS from the date of initiation of first-line treatment to death; tumor response based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria without being mandatory for the confirmation of response; time-to-response from the date of initiation of first-line treatment to partial response or complete response; and conversion rate to curative surgery. The transition of tumor-related symptoms was also evaluated for patients of Group 2, in accordance with the ESMO Guidelines 2012. The safety outcomes focused on skin and other specific toxicities (infusion reaction, hypomagnesemia, thrombus and interstitial lung disease) were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 ([@hyy189C17],[@hyy189C18]). Data were collected at baseline and every 2 months until the first 6 months after the initiation of first-line treatment and, thereafter, every 6 months up to 24 months.

Statistical analysis {#hyy189s11}
--------------------

The overall response rate (ORR), disease control rate, resection rate, liver resection rate and *R*~0~ resection rate were summarized along with the Clopper--Pearson exact confidence interval (CI). The differences in these rates among groups or subgroups were assessed by Fisher's exact test. We used the Kaplan--Meier method to estimate PFS, OS and relapse-free survival and used the log-rank test to compare the survival distributions of two or more groups. The pairwise test was performed as a post hoc analysis, and the adjusted *P* value was calculated in accordance with the Holm or Tukey method. All analyses were performed using SAS version 9.3.

Results {#hyy189s12}
=======

Patients' characteristics {#hyy189s13}
-------------------------

During the period from January 2012 to June 2013, 578 mCRC patients were enrolled in the study from 158 centers in Japan; of those, 562 patients from 152 centers met the inclusion criteria of the study. Out of these 562 patients, *KRAS* wild-type 538 (96%), *KRAS* mutation type 14 (2%), not measured 5 (1%) and unknown 5 (1%) were diagnosed with *KRAS* wild-type and mutation tumors, respectively (Table [1](#hyy189TB1){ref-type="table"}). There were 165 (29%), 224 (40%) and 173 (31%) patients classified into Groups 1, 2 and 3, respectively, in accordance with the ESMO consensus guidelines. Background characteristics are shown in Table [2](#hyy189TB2){ref-type="table"}. The proportions of patients with ECOG PS ≥ 1, high level of LDH and present primary tumor location were higher in Group 2 (45, 63 and 54%) than in Group 1 (21, 40 and 29%) or 3 (20, 38 and 14%). The demographics with regard to gender, age and *KRAS* status were well balanced among the three groups. Table 2.Regimens of cetuximab-containing chemotherapies in each ESMO guideline groupRegimensGroup 1Group 2Group 3*P* value^a^Total (*N* = 562)165 (100%)224 (100%)173 (100%)Oxaliplatin based (65.7%)115 (69.7%)147 (65.6%)107 (61.8%)0.1937 FOLFOX+Cmab94 (57.0%)116 (51.8%)63 (36.4%)0.0006 SOX+Cmab12 (6.4%)21 (9.2%)29 (16.7%)0.0103 Cape+Cmab9 (8.7%)10 (5.2%)15 (8.6%)0.2887Irinotecan based (30.1%)44 (26.7%)64 (28.4%)61 (35.6%)0.1437 FOLFIRI+Cmab33 (20.3%)54 (24.0%)36 (21.3%)0.6512 IRIS+Cmab10 (5.8%)6 (2.6%)19 (10.9%)0.0026 IRI+Cmab1 (0.6%)3 (1.3%)6 (3.4%)0.1352 IFL+Cmab01 (0.4%)0Cmab monotherapy (3.6%)6 (3.5%)10 (4.4%)4 (2.9%)0.6271Others+Cmab Combinations03 (1.3%)1 (0.6%)[^2][^3]

Treatment regimen {#hyy189s14}
-----------------

The cetuximab-containing regimens used in each group of patients are listed in Table [2](#hyy189TB2){ref-type="table"}. Oxaliplatin-based regimens seemed to be preferable over irinotecan-based chemotherapy in Japan; 65.7% of the patients received oxaliplatin-based chemotherapy combined with cetuximab, while 30.1% of the patients received irinotecan-based cetuximab-containing chemotherapy. Cetuximab monotherapy was used in 3.6% of patients in the study. The proportions of patients treated with FOLFOX (5-FU, leucovorin and oxaliplatin) + cetuximab were 57.0 and 51.8% in Groups 1 and 2, respectively. This was higher than the rate of 36.4% in Group 3 (*P* \< 0.001). The percentage of patients who received SOX (TS-1 and oxaliplatin) + cetuximab and IRIS (irinotecan + TS-1) + cetuximab were 16.7 and 10.9% in Group 3, which showed a tendency to be higher than those in Group 1 (6.4 and 5.8%, respectively) and Group 2 (9.2 and 2.6%, respectively).

Efficacy {#hyy189s15}
--------

The median OS (mOS) and median PFS (mPFS) were recorded as 27.3 (95% CI: 23.8--30.2) and 10.6 (9.4--11.4) months, respectively, in all eligible patients (Fig. [1](#hyy189F1){ref-type="fig"}A and D). In terms of regimens, the PFS was longer in patients treated with FOLFOX + cetuximab than in those treated with FOLFIRI + cetuximab (*P* = 0.0085). The mPFS was 12.1 (10.3--13.6) and 10.3 (8.5--11.3) months in patients treated with FOLFOX + cetuximab and FOLFIRI + cetuximab, respectively (Fig. [1](#hyy189F1){ref-type="fig"}C and F). Groups 1, 2 and 3 showed the mOS of 45.9 (38.1--NA), 16.7 (14.5--18.8) and 30.6 (23.2--34.8) months, respectively (*P* \< 0.0001). Pairwise test *P* values were \< 0.0001 for Group 1 vs. Group 2 or 3, and the *P* values were \< 0.0001 for Group 2 vs. Group 3 (Fig. [1](#hyy189F1){ref-type="fig"}B). The mPFSs of Groups 1, 2 and 3 were found to be 15.1 (13.0--18.4), 8.3 (6.8--9.5) and 9.3 (8.0--11.0) months, respectively (*P* \< 0.0001). The *P* value for the pairwise test for Group 1 vs. Group 2 or 3 in comparison to Group 2 vs. Group 3 (Fig. [1](#hyy189F1){ref-type="fig"}E) was found to be \< 0.0001. ORR was 56.9% in all evaluable patients (*n* = 531). In Groups 1, 2 and 3, the ORRs were 63.5, 55.6 and 59.1%, respectively (Table [3](#hyy189TB3){ref-type="table"}) (*P* = 0.3200). However, the complete response rate differed among them (*P* = 0.0356), with 5.1% in Group 1, 1.9% in Group 2 and 6.9% in Group 3. The medians of maximum tumor shrinkage (depth of response) were almost the same between groups (Table [3](#hyy189TB3){ref-type="table"}). Table 3.ORR, RR, DpR and TTF in each ESMO guideline groupGroup 1Group 2Group 3*P* value^a^**Response rate**Number of patients analyzed (*N* = 531)156216159Complete response8 (5.1%)4 (1.9%)11 (6.9%)0.03555Partial response91 (58.3%)116 (53.7%)83 (52.2%)0.5188Stable disease33 (21.1%)51 (23.6%)33 (20.8%)0.7807Progressive disease13 (8.3%)29 (13.4%)15 (9.4%)0.2462Not evaluable6 (3.8%)13 (6.0%)12 (7.5%)Unknown5 (3.2%)3 (1.4%)5 (3.1%)ORR (56.9%)99 (63.5%)120 (55.6%)94 (59.1%)0.3169Disease control rate (80.9%)132 (84.6%)171 (79.2%)127 (79.9%)0.3744**Depth of response**Number of patients analyzed (*N* = 473)145189139Median43.0%43.3%39.6%\<0.6511Interquartile range(20.6, 58.8)(11.9, 57.9)(15.0, 58.8)Range(0, 100%)(0, 100%)(0, 100%)Group 1Group 2Group 3*P* value^a^**Resection rate**Number of patients analyzed (*N* = 562)165224173Resection94 (57.0%)25 (11.2%)20 (11.6%)\<0.00001Liver resection66 (40.0%)10 (4.5%)11 (6.4%)\<0.00001*R*~0~ resection68 (41.2%)9 (4.0%)7 (4.0%)\<0.00001**Time to treatment failure**Number of patients analyzed (*N* = 562)165224173Median (day)126157.5175\<0.019Interquartile range(64.0, 250.0)(72.5, 269.0)(93.0, 322.0)Range (day)(0, 1204)(0, 1022)(0, 771)[^4][^5]

![Kaplan--Meier estimates for OS and PFS. OS and PFS in all patients (A and D) in Groups 1, 2 and 3 (B and E) and those in patients treated with FOLFOX + cetuximab and FOLFIRI + cetuximab (C and F, respectively). Two-sided *P* values were evaluated by the log-rank test. The median OS or PFS is shown in each figure with 95% CI. mOS, median OS; mPFS, median PFS; OS, overall survival; PFS, progression-free survival; CI, confidence interval.](hyy189f01){#hyy189F1}

The resection rate was higher in Group 1 than in Groups 2 and 3 (*P* \< 0.0001). Specifically, the resection, the hepatic resection and the *R*~0~ resection rates were found to be 57.0% (49.0--64.6%), 40.0% (32.5--47.9%) and 41.2% (33.6--49.1%) in Group 1 compared with 11.2% (7.4--16.0%), 4.5% (2.2--8.1%), and 4.0% (1.9--7.5%) in Group 2 and 11.6% (7.2--17.3%), 6.4% (3.2--11.1%) and 4.0% (1.6--8.2%) in Group 3 (Table [3](#hyy189TB3){ref-type="table"}). Among patients whose metastases were resected, the rates of *R*~0~ resection (Group 1, 2 and 3) were 72, 36 and 35%. Waterfall plots for each group are shown in Fig. [2](#hyy189F2){ref-type="fig"}.

![Waterfall plot. Tumor shrinkage from baseline is plotted in each group.](hyy189f02){#hyy189F2}

Tumor-related symptoms in Group 2 {#hyy189s16}
---------------------------------

The changes in tumor-related symptoms (CTCAE Grade 1≤) in Group 2 after initiation of the first-line treatment are summarized in Fig. [3](#hyy189F3){ref-type="fig"}. The common tumor-related symptoms were pain, fatigue and anorexia, from which 31.7, 22.2 and 14.8% of the patients suffered at baseline, but the proportions decreased to 8.6, 5.9 and 3.7%, respectively, at 24 weeks after the treatment in a time-dependent manner with a decreasing trend (*P* \< 0.0001).

![Time course of tumor-related symptoms and cetuximab-related adverse reactions (CTCAE Grade 1≤) in Group 2. Percentage of patients with tumor-related symptoms at each time point. Decreasing trend was evaluated by Chi-squared test for the proportions of each symptom and *P* value is shown at the right edge of the last time point in the figure.](hyy189f03){#hyy189F3}

Skin toxicities and hypomagnesemia {#hyy189s17}
----------------------------------

Skin reactions (CTCAE Grade 1≤) were frequently observed in the study and were considered to be cetuximab-related adverse events, including acneiform rash, xeroderma, paronychia, pruritus, fissures/skin ulcer and hair disorder. Acneiform rash was observed with the highest incidence of 68.6% of the patients at 8 weeks after cetuximab treatment was started, and the incidence gradually decreased to 50.2% at 24 weeks and to 18.2% at 1.5 years (Fig. [4](#hyy189F4){ref-type="fig"}). Other skin reactions developed gradually with a peak at 16 weeks, later than that of acneiform rash, and then decreased in frequency (Fig. [4](#hyy189F4){ref-type="fig"}). The incidence of hypomagnesemia increased gradually to 12.7% with a peak at 1 year after treatment and then decreased to 5.1% at 1.5 years (Fig. [4](#hyy189F4){ref-type="fig"}).

![Change in incidence of skin toxicities and hypomagnesemia (CTCAE Grade 1≤), which are known as cetuximab-related adverse reactions.](hyy189f04){#hyy189F4}

Discussion {#hyy189s18}
==========

This observational study showed the efficacy and safety of cetuximab-containing regimens as the first-line treatment for patients with mCRC in Japan and the difference of efficacies between patients who were classified into three groups according to the ESMO Guidelines 2012. To our knowledge, this is the first report comparing the efficacies of cetuximab-containing regimens among these three groups.

Among the patients enrolled in the present study, 70% of patients were classified into Groups 1 and 2. This might be because cetuximab-containing regiments may enhance the depth of response and early tumor shrinkage and are tended to be chosen in patients classified into Groups 1 and 2 in expectation of metastasectomy and reduction of tumor-related symptoms, respectively. The reasons for the higher proportion of patients with ECOG PS ≥ 1 and high level of LDH in Group 2 and without primary tumor in Group 3 may be that patients in Group 2 had tumor-related symptoms and patients in Group 3 had time to undergo resection of the primary tumor due to shrinkage of metastatic tumors. High proportion of patients with poor PS and high level of LDH led to shorter OS in Group 2 than in Group 1 or 3.

The present study showed that PFS and OS differed among the three groups while ORR was similar among them, showing that the efficacy of cetuximab-containing regimens was similar among the three groups. In Group 1, the higher resection rate likely led to longer PFS and OS. PFS of Group 2 was similar to that of Group 3, while OS was shorter than that of Group 3, suggesting that the baseline tumor burden in Group 2 was higher than that in Group 3. Although the present study was observational and a single-arm study, the higher resection rate in Group 1, the reduced rate of tumor-related symptoms in Group 2, and the similar OS to those in previous reports on Japanese trials suggested that cetuximab-containing regimens can achieve goals of chemotherapy in each group, showing that the classification in the ESMO Guidelines 2012 is useful in actual clinical practice ([@hyy189C15],[@hyy189C16]). In addition, a waterfall plot showed that receiving cetuximab-containing regimens resulted in good tumor shrinkage in each group, suggesting that patients whose goal is cytoreduction in the ESMO Guidelines 2016, which is nearly equivalent to Groups 1 and 2 in the ESMO Guidelines 2012, should receive treatment regimens containing anti-EGFR antibodies.

Previous studies did not compare the efficacy of FOLFOX + cetuximab with that of FOLFIRI + cetuximab. However, in the present study, the OS of patients treated with FOLFOX + cetuximab was similar to that of those treated with FOLFIRI + cetuximab. Although the PFS of patients treated with FOLFOX + cetuximab was longer than that of those treated with FOLFIRI + cetuximab, the fact that more patients were classified into Group 1 among those treated with FOLFOX + cetuximab than among those treated with FOLFIRI + cetuximab may have led to a longer PFS.

There were several limitations in the present study. First, it was an observational study; therefore no analysis was performed on proportions of *KRAS* mutation status or ECOG PS, and definitive conclusions cannot be drawn from the obtained results. Second, when this trial was planned, expanded *RAS* testing and *BRAF* testing have not been approved in Japan, yet. Additionally, it was not reported that primary tumor location can be predictive factor for the efficacy of anti-EGFR antibodies including cetuximab. Therefore, our results did not include *RAS* status, *BRAF* status and sidedness. Third, the present study featured several cetuximab-containing regimens, including non-standard regimens such as SOX or IRIS + cetuximab. This may have affected the results on the efficacy and safety. However, because a large number of patients were enrolled in the present study, and the efficacy and safety of cetuximab-containing regimens were similar to those in the FIRE-3 study, these findings seem to be reliable and might provide guidance for physicians in clinical practice.

Conclusions {#hyy189s19}
===========

This observational study suggests that cetuximab-containing regimens as the first-line treatment are effective and tolerable in Japanese patients with [mCRC]{.ul}, and that the classification of the ESMO Guidelines 2012 is applicable to Japanese patients.
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[^1]: CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group scale of performance status.

[^2]: Cape, capecitabine; Cmab, Cetuximab; ESMO, European Society for Medical Oncology; SOX, TS-1 and oxaliplatin.

[^3]: ^a^By two-tailed Fisher's exact test.

[^4]: ORR, overall response rate; RR, resection rate; DpR, depth of response; TTF, time to treatment failure.

[^5]: ^a^Overall *P* value for the three groups was evaluated by Fisher's exact test. When it was \<0.05, post hoc pairwise comparisons by Fisher's exact test were conducted, where multiplicity was adjusted by Holm's method.
